secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2023-09-25T23:59:59+00:00
Accession:  0001193125-23-241345
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma updates corporate presentation for Q4 2023 investor meetings
-----------------------------------------------------------------------

- Company posted updated corporate presentation on its website and furnished as Exhibit 99.1.
- Presentation covers pipeline, clinical data, and commercial strategy for neffy (epinephrine nasal spray).
- No financial updates or forward guidance included in the filing or presentation summary provided.
- Presentation is furnished under Regulation FD; not incorporated by reference into SEC filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523241345/0001193125-23-241345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523241345/d557739d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-241345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer